ESR1 and breast carcinoma: Since Ano1 overexpression did not correlate with clinical stage and histological grade in ER-negative, PR-positive, PR-negative, and HER2-postive tumors, cell-type specific mechanisms may be responsible for different roles of Ano1 in breast cancer cells with different ER, PR, and HER2 status.